Log In
BCIQ
Print this Print this
 

miRview meso

Also known as: ProOnc MesotheliomaDx

  Manage Alerts
Collapse Summary General Information
Company Rosetta Genomics Ltd.
DescriptionQRT-PCR test based on the expression of 3 microRNAs and 1 small RNA for discriminating pleural mesothelioma from other malignancies
Molecular Target Not applicable
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsDifferentiate malignant pleural mesothelioma (MPM) from other carcinomas in the lung and pleura
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$8.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

04/20/2009

Undisclosed

$8.0M

Undisclosed

Get a free BioCentury trial today